Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Stanford nixes industry-funded CME
The church-and-state separation of drugmakers and continuing medical education continues apace. Now it's Stanford's medical school that's refusing to take industry funding for specific CME programs or courses. The school won't accept money or in-kind help like equipment or supplies or services. Nor will it let for-profit CME companies that take industry money deliver their courses on campus.
Stanford joins a handful of other institutions that have curtailed their industry-funded CME recently. Memorial Sloan-Kettering cut itself off of industry funding for CME, the Wall Street Journal Health Blog reminds us, and Pfizer recently came at the problem from a different direction by saying it would no longer fund CME courses offered by for-profit companies.
What will Stanford accept? Well, it will take contributions to a pool of money that the university can then allocate as it sees fit. About half a dozen other med schools have created similar pools. It's an idea that could catch on; in fact, the CME accreditation body has been considering establishing a centralized pool for industry contributions. The money would be divvied up by medical societies.
- read the WSJ Health Blog post
- see the New York Times story
Related Articles:
AMA won't ban industry-funded education
Arms twisted, pharma promises CME disclosure
Med schools tight with drugmakers
GSK to report organization grants
Pfizer to stop funding for-profit CME
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


